{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:38:58Z","timestamp":1767706738865,"version":"3.37.3"},"reference-count":41,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"unspecified","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_19047"],"award-info":[{"award-number":["MC_PC_19047"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,1,25]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Sarcopenia is the age-associated loss of muscle mass and strength. Nicotinamide adenine dinucleotide (NAD) plays a central role in both mitochondrial function and cellular ageing processes implicated in sarcopenia. NAD concentrations are low in older people with sarcopenia, and increasing skeletal muscle NAD concentrations may offer a novel therapy for this condition. Acipimox is a licensed lipid-lowering agent known to act as an NAD precursor. This open-label, uncontrolled, before-and-after proof-of-concept experimental medicine study will test whether daily supplementation with acipimox improves skeletal muscle NAD concentrations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>Sixteen participants aged 65 and over with probable sarcopenia will receive acipimox 250\u2009mg and aspirin 75\u2009mg orally daily for 4 weeks, with the frequency of acipimox administration being dependent on renal function. Muscle biopsy of the vastus lateralis and MRI scanning of the lower leg will be performed at baseline before starting acipimox and after 3 weeks of treatment. Adverse events will be recorded for the duration of the trial. The primary outcome, analysed in a per-protocol population, is the change in skeletal muscle NAD concentration between baseline and follow-up. Secondary outcomes include changes in phosphocreatine recovery rate by<jats:sup>31<\/jats:sup>P magnetic resonance spectroscopy, changes in physical performance and daily activity (handgrip strength, 4 m walk and 7-day accelerometry), changes in skeletal muscle mitochondrial respiratory function, changes in skeletal muscle mitochondrial DNA copy number and changes in NAD concentrations in whole blood as a putative biomarker for future participant selection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>The trial is approved by the UK Medicines and Healthcare Products Regulatory Agency (EuDRACT 2021-000993-28) and UK Health Research Authority and Northeast \u2013 Tyne and Wear South Research Ethics Committee (IRAS 293565). Results will be made available to participants, their families, patients with sarcopenia, the public, regional and national clinical teams, and the international scientific community.<\/jats:p><\/jats:sec><jats:sec><jats:title>Protocol<\/jats:title><jats:p>Acipimox feasibility study Clinical Trial Protocol V.2 2\/11\/21.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>The ISRCTN trial database (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"ISRCTN87404878\">ISRCTN87404878<\/jats:ext-link>).<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2023-076518","type":"journal-article","created":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T02:43:54Z","timestamp":1717296234000},"page":"e076518","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["A study protocol to investigate if acipimox improves muscle function and sarcopenia: an open-label, uncontrolled, before-and-after experimental medicine feasibility study in community-dwelling older adults"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"isrctn87404878","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-9952","authenticated-orcid":false,"given":"Claire","family":"McDonald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Alderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew G","family":"Birkbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Del Din","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grainne G","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kieren","family":"Hollingsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Massarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Rochester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avan AP","family":"Sayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huizhong","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Tuppen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1967-0990","authenticated-orcid":false,"given":"Miles D","family":"Witham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"2024053113473511000_14.2.e076518.1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afs197"},{"key":"2024053113473511000_14.2.e076518.2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afu115"},{"key":"2024053113473511000_14.2.e076518.3","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaa123"},{"key":"2024053113473511000_14.2.e076518.4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.maturitas.2017.04.007","article-title":"Sarcopenia as a Predictor of all-cause mortality among community-dwelling older people: a systematic review and meta-analysis","volume":"103","author":"Liu","year":"2017","journal-title":"Maturitas"},{"key":"2024053113473511000_14.2.e076518.5","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12411"},{"key":"2024053113473511000_14.2.e076518.6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00223-018-0478-1","article-title":"Health care costs associated with muscle weakness: A UK population-based estimate","volume":"104","author":"Pinedo-Villanueva","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"2024053113473511000_14.2.e076518.7","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afy169"},{"key":"2024053113473511000_14.2.e076518.8","article-title":"Mitochondrial impairment in Sarcopenia","volume":"10","author":"Bellanti","year":"2021","journal-title":"Biology (Basel)"},{"key":"2024053113473511000_14.2.e076518.9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0925-4439(94)90061-2","article-title":"Decline with age of the respiratory-chain activity in human Skeletal-muscle","volume":"1226","author":"Boffoli","year":"1994","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"2024053113473511000_14.2.e076518.10","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2018.01883","article-title":"Mitochondria as a target for mitigating Sarcopenia","volume":"9","author":"Coen","year":"2018","journal-title":"Front Physiol"},{"key":"2024053113473511000_14.2.e076518.11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/crt2.56","article-title":"Effects of Nicotinamide Adenine Dinucleotide precursors on measures of physical performance and physical frailty: A systematic review","volume":"7","author":"Barker","year":"2022","journal-title":"JCSM Clinical Reports"},{"key":"2024053113473511000_14.2.e076518.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.05.006"},{"key":"2024053113473511000_14.2.e076518.13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13694-1","article-title":"Mitochondrial oxidative capacity and NAD biosynthesis are reduced in human Sarcopenia across Ethnicities","volume":"10","author":"Migliavacca","year":"2019","journal-title":"Nat Commun"},{"key":"2024053113473511000_14.2.e076518.14","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0667"},{"key":"2024053113473511000_14.2.e076518.15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1152\/jappl.1993.74.1.133","article-title":"Endogenous substrate oxidation during exercise and variations in breath 13Co2\/12Co2","volume":"74","author":"Gautier","year":"1993","journal-title":"J Appl Physiol (1985)"},{"key":"2024053113473511000_14.2.e076518.16","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.69.809.197"},{"key":"2024053113473511000_14.2.e076518.17","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00043.2014"},{"key":"2024053113473511000_14.2.e076518.18","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00475.2010"},{"key":"2024053113473511000_14.2.e076518.19","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1210\/jc.2015-3696","article-title":"Metabolic effects of long-term reduction in free fatty acids with Acipimox in obesity: A randomized trial","volume":"101","author":"Makimura","year":"2016","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"2024053113473511000_14.2.e076518.20","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-022-06544-x","article-title":"Acipimox in mitochondrial myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of Acipimox in adult patients with mitochondrial myopathy","volume":"23","author":"Abouhajar","year":"2022","journal-title":"Trials"},{"key":"2024053113473511000_14.2.e076518.21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/rco2.38","article-title":"Recruitment strategies for Sarcopenia trials: lessons from the LACE randomized controlled trial","volume":"4","author":"Witham","year":"2021","journal-title":"JCSM Rapid Communications"},{"key":"2024053113473511000_14.2.e076518.22","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-009-0246-z"},{"key":"2024053113473511000_14.2.e076518.23","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"2024053113473511000_14.2.e076518.24","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-011-0006-8"},{"key":"2024053113473511000_14.2.e076518.25","doi-asserted-by":"crossref","first-page":"111884","DOI":"10.1016\/j.exger.2022.111884","article-title":"Advancing our understanding of skeletal muscle across the Lifecourse: protocol for the Mass_Lifecourse study and characteristics of the first 80 participants","volume":"166","author":"Dodds","year":"2022","journal-title":"Exp Gerontol"},{"key":"2024053113473511000_14.2.e076518.26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.exger.2018.09.020","article-title":"Mitochondrial respiratory chain function and content are preserved in the Skeletal muscle of active very old men and women","volume":"113","author":"Dodds","year":"2018","journal-title":"Exp Gerontol"},{"key":"2024053113473511000_14.2.e076518.27","doi-asserted-by":"crossref","unstructured":"Strehler BL . Adenosine-5\u2032-Triphosphate and creatine phosphate determination with Luciferase. Methods of Enzymatic Analysis: Elsevier 1974:2112\u201326.","DOI":"10.1016\/B978-0-12-091304-6.50065-3"},{"key":"2024053113473511000_14.2.e076518.28","doi-asserted-by":"publisher","DOI":"10.1007\/BF01753355"},{"key":"2024053113473511000_14.2.e076518.29","doi-asserted-by":"crossref","DOI":"10.1038\/srep15037","article-title":"A novel Immunofluorescent assay to investigate oxidative Phosphorylation deficiency in mitochondrial myopathy: understanding mechanisms and improving diagnosis","volume":"5","author":"Rocha","year":"2015","journal-title":"Sci Rep"},{"key":"2024053113473511000_14.2.e076518.30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114462","article-title":"Accurate measurement of mitochondrial DNA deletion level and copy number differences in human Skeletal muscle","volume":"9","author":"Grady","year":"2014","journal-title":"PLoS One"},{"key":"2024053113473511000_14.2.e076518.31","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afr051"},{"key":"2024053113473511000_14.2.e076518.32","doi-asserted-by":"publisher","DOI":"10.1093\/geronj\/49.2.M85"},{"key":"2024053113473511000_14.2.e076518.33","unstructured":"Axivity . Ax6 Datasheet 6-axis logging movement sensor. 2023. Available: https:\/\/axivity.com\/files\/resources\/AX6_Data_Sheet.pdf"},{"key":"2024053113473511000_14.2.e076518.34","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/gerona\/glx254","article-title":"Analysis of free-living gait in older adults with and without Parkinson\u2019s disease and with and without a history of falls: identifying generic and disease-specific characteristics","volume":"74","author":"Del Din","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2024053113473511000_14.2.e076518.35","first-page":"1198","article-title":"Falls risk in relation to activity exposure in high-risk older adults","volume":"75","author":"Del Din","year":"2020","journal-title":"The Journals of Gerontology"},{"key":"2024053113473511000_14.2.e076518.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.04.013"},{"key":"2024053113473511000_14.2.e076518.37","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1148\/radiol.14141191","article-title":"Improving highly accelerated fat fraction measurements for clinical trials in muscular dystrophy: origin and quantitative effect of R2* changes","volume":"275","author":"Loughran","year":"2015","journal-title":"Radiology"},{"key":"2024053113473511000_14.2.e076518.38","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8547-3"},{"key":"2024053113473511000_14.2.e076518.39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jcsm.12655","article-title":"The role of novel motor unit magnetic resonance imaging to investigate motor unit activity in ageing Skeletal muscle","volume":"12","author":"Birkbeck","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2024053113473511000_14.2.e076518.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2013.05.018"},{"key":"2024053113473511000_14.2.e076518.41","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s41999-020-00310-5","article-title":"The identification of probable Sarcopenia in early old age based on the SARC-F tool and clinical suspicion: findings from the 1946 British birth cohort","volume":"11","author":"Dodds","year":"2020","journal-title":"Eur Geriatr Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-076518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T02:44:12Z","timestamp":1717296252000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-076518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,27]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/bmjopen-2023-076518"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-076518","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}